Monitor the tender offer statement expected to be filed June 3, 2026 for detailed terms of the option exchange. The rejection of executive option exchange suggests potential retention risk for senior management, but no immediate trading catalyst.
RGNX drugs
RGNX drug pipeline →- ▲ surabgene lomparvovec 7/10 Phase 3
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned)
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026)
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $6.69entry
- T+1 · 6mo ago +2.84%α +2.44% · $6.88
- T+5 · 5mo ago −8.37%α −4.55% · $6.13
- T+20 · 5mo ago +98.51%α +99.51% · $13.28
- T+60 · 3mo ago +40.06%α +37.56% · $9.37
Price Chart
How similar events traded
Executive Summary
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II directors, ratified PwC as auditor, approved non-executive stock option exchange program, and did NOT approve a similar program for executives. The company commenced the non-executive option exchange program on June 3, 2026, with an offer period running through July 1, 2026. This is a routine governance and compensation event with no material financial impact disclosed.
Key Facts
- Annual Meeting held May 29, 2026 with 42,818,883 shares represented (~82.95% of eligible shares)
- Shareholders elected Jean Bennett, A.N. Jerry Karabelas, and Daniel Tass as Class II directors
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026
- Approved non-executive employee stock option exchange program (26.4M for, 8.9M against)
- Did NOT approve executive stock option exchange program (14.1M for, 21.0M against)
- Non-executive option exchange program commenced June 3, 2026; offer period ends July 1, 2026
- Exchange program applies to options with exercise price ≥ $18.00; new options priced at fair market value on grant date
- Company states exchange program not expected to result in significant change to stock compensation expense
Financial Impact
No material financial impact disclosed; company states stock compensation expense not expected to change significantly
Risk Factors
- Executive option exchange rejection may signal dissatisfaction with pay structure or governance
- Option exchange could modestly reduce dilution if underwater options are surrendered
- No financial guidance or operational update provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254590 |
| Document: 0001193125-26-254590-index.html | 0001193125-26-254590 |
| Document: 0001193125-26-254590.txt | 0001193125-26-254590 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers